Non-alcoholic steatohepatitis and cancer.

Hepatocellular carcinoma (HCC) is part of the natural history of non-alcoholic steatohepatitis (NASH). A significant proportion of people who have cryptogenic cirrhosis develop HCC. NASH-related cirrhosis carries a substantial risk for early HCC development. Diagnosis of HCC often is made at first referral; the tumor usually is large with multiple localizations. Patients who have obesity or diabetes are at risk for HCC and a variety of cancers. Given the epidemic of obesity and diabetes, the incidence of NASH-related HCC is expected to increase. In addition to developing new diagnostic tools and pharmacologic therapies, efforts should be directed at preventing non-alcoholic fatty liver disease.

[1]  Lu-Yu Hwang,et al.  Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus , 2002, Hepatology.

[2]  R O Morgan,et al.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study , 2005, Gut.

[3]  C. Chang,et al.  Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin. , 1987, The Journal of clinical investigation.

[4]  H. Zhu,et al.  Mitochondrial adaptations to obesity-related oxidant stress. , 2000, Archives of biochemistry and biophysics.

[5]  K. Peltekian,et al.  Review article: the changing epidemiology of hepatocellular carcinoma in Canada , 2005, Alimentary pharmacology & therapeutics.

[6]  H. Adami,et al.  Role of diabetes mellitus in the etiology of hepatocellular carcinoma. , 2000, Journal of the National Cancer Institute.

[7]  K. Yamazaki,et al.  Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. , 2001, Journal of submicroscopic cytology and pathology.

[8]  Ming-yi Li,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. , 2003, World journal of gastroenterology.

[9]  A. McCullough,et al.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[10]  G. Schweizer-Groyer,et al.  An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. , 2004, Biochemical pharmacology.

[11]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[12]  S. Caldwell,et al.  Obesity and hepatocellular carcinoma. , 2004, Gastroenterology.

[13]  Candy S. Lee,et al.  Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Kihara,et al.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Taniai,et al.  Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH , 2004, Journal of Gastroenterology.

[16]  G. Gores,et al.  Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. , 2003 .

[17]  S. Wen,et al.  Association of obesity and cancer risk in Canada. , 2004, American journal of epidemiology.

[18]  Y. Ahn.  Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. , 1996, Gut.

[19]  F. Itoh,et al.  Hepatocellular carcinoma with silent and cirrhotic non‐alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder , 2006, Pathology international.

[20]  Wei Zhang,et al.  Function of oval cells in hepatocellular carcinoma in rats. , 2004, World journal of gastroenterology.

[21]  E. Abdalla,et al.  Obesity and diabetes as a risk factor for hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  M Linet,et al.  Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. , 1997, Journal of the National Cancer Institute.

[23]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[24]  E. Schiff,et al.  Viral pathogenesis of hepatocellular carcinoma in the United States , 1993, Hepatology.

[25]  B. Henderson,et al.  Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. , 1991, Journal of the National Cancer Institute.

[26]  S. Feig.  IARC Handbooks of Cancer Prevention , 2003 .

[27]  P. Hayashi,et al.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study , 2003, American Journal of Gastroenterology.

[28]  H. El‐Serag,et al.  Risk factors for the rising rates of primary liver cancer in the United States. , 2000, Archives of internal medicine.

[29]  H. Adami,et al.  A prospective study of obesity and cancer risk (Sweden) , 2004, Cancer Causes & Control.

[30]  Y. Yoon,et al.  Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[32]  Julie H. Campbell,et al.  J. Submicrosc. Cytol. Pathol. , 2000 .

[33]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[34]  C. Christoffersen,et al.  Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor , 1997, Diabetologia.

[35]  G. Loss,et al.  Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.

[36]  H. El‐Serag,et al.  The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans , 2001, American Journal of Gastroenterology.

[37]  P. Giral,et al.  Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.

[38]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[39]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[40]  J. Ludwig,et al.  Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. , 2002, Journal of hepatology.

[41]  R. Paraná,et al.  Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? , 2000 .

[42]  P. Scherer,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0580 Minireview: The Adipocyte—At the Crossroads of Energy Homeostasis, Inflammation, and Atherosclerosis , 2022 .

[43]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[44]  H. Adami,et al.  Excess risk of primary liver cancer in patients with diabetes mellitus. , 1996, Journal of the National Cancer Institute.

[45]  G. Marchesini,et al.  Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[46]  Teruaki Kimura,et al.  Hepatocellular carcinoma with nonalcoholic steatohepatitis , 2004, Journal of Gastroenterology.

[47]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[48]  K. Tsuneyama,et al.  Hepatocellular carcinoma arising in non‐alcoholic steatohepatitis , 2001, Pathology international.

[49]  B. Yeap,et al.  Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. , 2005, Carcinogenesis.

[50]  R. Hoover,et al.  Obesity and cancer risk among white and black United States veterans , 2004, Cancer Causes & Control.

[51]  H. El‐Serag,et al.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.

[52]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[53]  J. Olsen,et al.  Obesity and cancer risk: a Danish record-linkage study. , 1994, European journal of cancer.

[54]  M. Lane,et al.  Leptin regulates proinflammatory immune responses. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[56]  V. P. Chacko,et al.  Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? , 2001, Cancer research.

[57]  M. Tang,et al.  The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. , 2002, Carcinogenesis.

[58]  P. Thuluvath,et al.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.

[59]  M. Hashizume,et al.  Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. , 2000, Cancer research.

[60]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[61]  M. Kastan,et al.  Induction of apoptosis by tumor suppressor genes and oncogenes. , 1995, Seminars in cancer biology.

[62]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[63]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[64]  J. Reddy,et al.  Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. , 2003, Current molecular medicine.

[65]  S. Caldwell,et al.  The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. , 2004, Journal of hepatology.

[66]  J. Marrero,et al.  NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States , 2002, Hepatology.

[67]  D. Lobo,et al.  Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. , 2004, Journal of hepatology.

[68]  Y. Ueda,et al.  Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid , 2005, Virchows Archiv.